Free Trial

Trevi Therapeutics Q3 2024 Earnings Report

Trevi Therapeutics logo
$6.50 -0.03 (-0.46%)
As of 03/28/2025 04:00 PM Eastern

Trevi Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
-$0.08

Trevi Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Trevi Therapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

Trevi Therapeutics Earnings Headlines

B. Riley Predicts Weaker Earnings for Trevi Therapeutics
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Leerink Partnrs Issues Optimistic Outlook for TRVI Earnings
Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at B. Riley
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst
See More Trevi Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Trevi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevi Therapeutics and other key companies, straight to your email.

About Trevi Therapeutics

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

View Trevi Therapeutics Profile

More Earnings Resources from MarketBeat